Sen. John Boozman Buys Eli Lilly and Company (NYSE:LLY) Shares

Key Points

• Senator John Boozman purchased between $1,001 and $15,000 in shares of Eli Lilly and Company (NYSE: LLY) on August 11th, highlighting his investment in the pharmaceutical firm.
• Eli Lilly reported a record earnings per share of $6.31 for the last quarter, exceeding analyst estimates by $0.72, with a significant 37.6% year-over-year revenue increase to $15.56 billion.
• The company has a dividend yield of 0.8% after recently declaring a quarterly dividend of $1.50 per share, emphasizing its financial stability and commitment to shareholders.

Senator John Boozman (R-Arkansas) recently bought shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on September 12th, the Senator disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on August 11th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 8/22/2025.
• Sold $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 8/22/2025.
• Sold $1,001 - $15,000 in shares of Micron Technology NASDAQ: MU on 8/22/2025.
• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/22/2025.
• Sold $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 8/11/2025.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of iShares MBS ETF NASDAQ: MBB on 8/1/2025.
• Sold $1,001 - $15,000 in shares of iShares MSCI EAFE ETF NYSEARCA: EFA on 8/1/2025.
• Purchased $1,001 - $15,000 in shares of Goldman Sachs ActiveBeta Emerging Markets Equity ETF NYSEARCA: GEM on 8/1/2025.
• Purchased $1,001 - $15,000 in shares of iShares 7-10 Year Treasury Bond ETF NASDAQ: IEF on 8/1/2025.

Eli Lilly and Company Stock Performance

LLY traded down $7.13 during trading on Monday, hitting $748.26. 2,787,993 shares of the stock were exchanged, compared to its average volume of 3,436,359. The firm has a market capitalization of $708.20 billion, a P/E ratio of 48.91, a PEG ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The stock has a fifty day moving average price of $740.54 and a two-hundred day moving average price of $774.30. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 EPS. The company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last quarter. Insiders own 0.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. UBS Group decreased their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Guggenheim decreased their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $941.35.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Duquesne Family Office LLC lifted its holdings in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $570,000. LS Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the last quarter. Cutter Capital Management LP acquired a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $14,866,000. Finally, Prism Advisors Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $207,000. Institutional investors own 82.53% of the company's stock.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas' U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman's academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.